CDXS - コデクシス （Codexis Inc.） コデクシスCDXSのチャート
CDXSの企業情報
| symbol | CDXS |
|---|---|
| 会社名 | Codexis Inc （コデクシス） |
| 分野（sector） | Basic Industries 素材 |
| 産業（industry） | Major Chemicals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 コデクシス（Codexis Inc.）はタンパク質エンジニアリング会社である。同社は、医薬品およびファインケミカルの商業用製造のための生体触媒の開発に従事している。同社はパフォーマンス酵素及び新規の生物療法剤2つの事業を運営する。同社は、小規模から商業的な量までの酵素最適化サービスを提供し、また生体触媒製品を開発する。また、活性医薬成分、ファインケミカル、食品成分の製造プロセスの開発に従事する。同社のCodeEvolverは、タンパク質工学の技術プラットフォームであり、医薬品市場における製品である。同社は、食品および食品原料、動物飼料、香料、香料及び農薬を含む各産業にサービスを提供する。 コデクシスは米国のバイオテクノロジ―企業。医薬品及び精製化学製品市場のための生体触媒を開発、生産。製薬会社のほか、食品、動物飼料、ポリマ―、香味及び香料、農薬などの製造会社に、生体触媒である酵素を提供する。同社は2002年に設立し、カリフォルニア州に本社を置く。 Codexis is a leading enzyme engineering company that applies its proprietary CodeEvolver® technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis' proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes. |
| 本社所在地 | 200 Penobscot Drive Redwood City CA 94063 USA |
| 代表者氏名 | Bernard J. Kelley バーナード・J.・ケリー |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 650-421-8100 |
| 設立年月日 | 37257 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2010年 |
| 従業員数 | 116人 |
| url | www.codexis.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cdxs |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -16.71000 |
| 終値（lastsale） | 16.5 |
| 時価総額（marketcap） | 882953791.5 |
| 時価総額 | 時価総額（百万ドル） 917.73680 |
| 売上高 | 売上高（百万ドル） 59.28700 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 864.29880 |
| 当期純利益 | 当期純利益（百万ドル） -51.78500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Codexis Inc. revenues increased 51% to $27.6M. Net loss decreased 39% to $8.4M. Revenues reflect EMEA segment increase of 70% to $8.8M America segment increase of 56% to $9.7M. Lower net loss reflects Interest income increase from $67K to $245K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.31 to -$0.17. |
CDXSのテクニカル分析
CDXSのニュース
Is Codexis Inc. (NASDAQ:CDXS) stock a better investment at this time? 2022/07/04 16:00:00 US Post News
Currently, Codexis Inc.’s (CDXS) stock is trading at $10.88, marking a gain of 4.02% from last night’s close. At this price, the stock is -74.10% below its 52-week high of $42.01 and 34.16% above its 52-week low of $8.11. Based on the past 30-day period, the stock price is -6.04% below the high and +34.16% … Is Codexis Inc. (NASDAQ:CDXS) stock a better investment at this time? Read More »
Companies - Codexis, Inc. Given Consensus Rating of “Buy” by Brokerages 2022/06/19 07:15:09 Business Mag
Codexis, Inc. has been given an average rating of “Buy” by the six research firms that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the…
Codexis rises 8% on publication of research for protein modification 2022/06/17 13:52:59 Seeking Alpha
Codexis <> along with Merck (MRK) announced the development of a suite of enzymes and their application for site-selective synthesis of insulin bioconjugates.The data were…
Codexis Inc. (NASDAQ:CDXS): Buy, Sell Or Hold At $9.16? 2022/06/11 13:00:00 Marketing Sentinel
In last trading session, Codexis Inc. (NASDAQ:CDXS) saw 0.55 million shares changing hands with its beta currently measuring 1.98. Company’s recent per share price level of $9.16 trading at -$0.45 or -4.68% at ring of the bell on the day assigns it a market valuation of $623.61M. That closing price of CDXS’s stock is at … Codexis Inc. (NASDAQ:CDXS): Buy, Sell Or Hold At $9.16? Read More »
Boom Or Bust: Where Does Codexis Inc. (NASDAQ: CDXS) Stock Go From Here? 2022/06/04 13:30:00 Marketing Sentinel
During the last session, Codexis Inc. (NASDAQ:CDXS)’s traded shares were 0.81 million, with the beta value of the company hitting 1.99. At the end of the trading day, the stock’s price was $10.14, reflecting an intraday loss of -4.07% or -$0.43. The 52-week high for the CDXS share is $42.01, that puts it down -314.3 … Boom Or Bust: Where Does Codexis Inc. (NASDAQ: CDXS) Stock Go From Here? Read More »
Codexis and Kalsec Announce Expanded Collaboration for Supply of Novel Enzyme to Sustainably Produce Natural Clean-Label Beverage Ingredient 2021/07/26 20:05:00 Intrado Digital Media
REDWOOD CITY, Calif. and KALAMAZOO, Mich., July 26, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Kalsec, Inc., a leading global producer of natural spice and herb extracts, colors, food protection and hop extracts for the food and beverage industry, announced that the companies have expanded their research collaboration and entered into an exclusive supply agreement for a novel enzyme to produce Kalsecs newest natural hop acid.
Codexis Announces Completion of CodeEvolver® License Technology Transfer with Global Pharmaceutical Leader 2021/07/14 20:05:00 Intrado Digital Media
REDWOOD CITY, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the completion of the CodeEvolver ® platform technology transfer with Novartis Pharma AG (Novartis) today. In May 2019, the two companies signed a platform technology transfer and license agreement, under which Novartis has a non-exclusive license to CodeEvolver ® to develop novel performance enzymes for use in the manufacture of pharmaceutical products.
Codexis Earns Milestone Payment from GlaxoSmithKline 2021/07/07 20:05:00 Intrado Digital Media
REDWOOD CITY, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced it earned a significant milestone payment related to the licensing of its proprietary CodeEvolver® protein engineering platform technology to GlaxoSmithKline (GSK). This milestone marks the advancement of the commercialization of an enzyme, generated using CodeEvolver under the licensing agreement, that is engineered to improve a key step in the manufacturing process for a currently undisclosed drug. The milestone, which was expected in the second half of 2021, was recorded as revenue in the second quarter.
Should You Expect A Quick Recovery From Codexis, Inc. (NASDAQ:CDXS) After -31.14% Decline From High? 2021/06/26 08:32:00 Investor Newsletter
Codexis, Inc. (NASDAQ:CDXS)s traded shares stood at 636,886 during the last session, with the companys beta value hitting 1.27. At the close of trading, the stocks price was $22.54, to imply an increase of 0.94% or $0.21 in intraday trading. The CDXS shares 52-week high remains $29.56, putting it -31.14% down since that peak but []
TSMC, BYD, Komatsu, Surface Oncology And 3D Systems — What Cathie Wood's Ark Bought And Sold Today 2021/03/24 03:47:13 Benzinga
Every night, Cathie Wood’s Ark Investment Management sends out an email listing the stocks that were bought or sold by the firm's ETFs that day. In recent months, the emails have been known to cause certain stocks to see a spike in the after-hours session. Here’s a list of what the hedge fund bought or sold on Tuesday. 3D Systems Corp (NYSE: DDD ): Bought 558,900 shares of the printing engineering company, representing about 0.46% of the ETF. 3D shares closed 9.62% lower at $26.22 on Tuesday and rose 1.07% in the after-hours. It has a 52-week high of $56.5 and low of $4.60. Accolade Inc (NASDAQ: ACCD ): Bought 38,112 shares of the personalized health-tech company, representing about 0.016% of the company. Accolade shares closed 2.2% lower at $42.03 on Tuesday and were further down 1.26% in the after-hours. It has a 52-week high of $62.25 and low of $28.68. Codexis Inc (NASDAQ: CDXS ): Bought 138,712 shares in the protein engineering company, representing just about 0.032% of the ETF. Codexis shares closed 2.44% lower at $21.95 on Tuesday.
Global Proteinase K Market Analysis Report 2020-2027 Featuring Key players - Merck, BBI Solutions, Codexis, SBS Genetech, Hoffmann-La Roche, Amicogen Amano Enzyme & Advanced Enzymes Technologies - ResearchAndMarkets.com 2021/03/01 13:33:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Proteinase K Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Area; By Form, By Regions; Segment Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering. The global proteinase K market size is predicted to reach US$ 107.5 Million by 2027 The report "Proteinase K Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Area (Infectious diseases, Diabetes, Oncology, Cardiology, Nephrology, Autoimmune diseases, N
Phenylketonuria Treatment Market Analysis Released in Latest Industry Report 2020: BioMarin, Codexis, Erytech Pharma, SOM Innovation Biotech, Retrophin 2021/02/26 08:08:42 OpenPR
Global Phenylketonuria Treatment Market Analysis to 2027 is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Phenylketonuria Treatment market with detailed
Codexis Factors Likely to Have Influenced Earnings Results Stock market Insights & financial analysis 2021/02/24 21:24:00 Stock Market Daily
Codexis announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
Codexis (CDXS) may be moving closer to profitability, after beating slowdown 2021/01/21 18:34:23 AlphaStreet
Biosciences company Codexis, Inc. (NASDAQ: CDXS) has emerged stronger from a rough patch, supported mainly by the resilience of its partners to the virus crisis. The recent improvement in fiscal […] The post Codexis (CDXS) may be moving closer to profitability, after beating slowdown first appeared on AlphaStreet .